Xinkang^® Lacosamide Tablets are the first third-generation novel antiepileptic drug in China, approved for market in January 2019. It is now available in over 58 countries including the U.S., EU, Japan, and China, and has been used by over 500,000 epilepsy patients globally. Due to its unique mechanism of action, safety, and efficacy, Lacosamide has become one of the most widely used antiepileptic drugs worldwide. In January 2019, Xinkang® Lacosamide Tablets were approved for priority review in China, bringing new treatment hope for epilepsy patients in China.